Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. junior Avg
|
|
New words:
Additionally, American, ASCO, ASTRO, August, Bank, card, chronic, cisplatin, CKD, collateral, compelled, deal, deferral, deposit, doubt, driven, eGFR, exploration, guarantee, highlight, hoc, IMRT, kidney, meaningful, Oncology, opportunity, perception, post, predefined, prospective, realization, regimen, reinforced, renal, satisfaction, satisfactory, senior, showing, Society, spend, TD, thereon
Removed:
NaN
Filing tables
Filing exhibits
Related press release
GRTX similar filings
Filing view
External links
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Galera Therapeutics, Inc. (the “Company”) for the period ended September 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
(1)
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: November 9, 2022 | By: | /s/ Christopher Degnan |
|
| Christopher Degnan Chief Financial Officer |